SURVYR

EW

Edwards Lifesciences Corporation
$91.78
+$0.96 (1.06%)Oct 28 close
Health CareS&P 500 CompareTechnicals
1M3M6M1Y2Y
-8%-1%+6%+12%+19%Oct 2025Oct 2026Apr 202652w high $96.2952w low $74.66
EWSPY
Wall St. Highest PT $110.00 (+19.9%) Wall St. Avg PT $101.39 (+10.5%)
$76$85$95$104$113POC $86Hi $110Avg $101
Underwater Drawdown %Max DD -13.2%Current -3.6%
0.0%-13.2%
Relative Strength vs SPY-0.4% vs SPYUnderperforming
+15%0%-15%
1W
+$3.38 (3.82%)
1M
+$4.95 (5.70%)
3M
+$6.02 (7.02%)
6M
+$10.56 (13.00%)
YTD
+$6.53 (7.66%)
1Y
+$9.59 (11.67%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
27 analysts · mean score 1.63
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$91.78
Average target$101.39
+$9.61 (+10.5%) upsideaverage target vs current price
CurrentAverageMedian
Low$84.00
Median$101.39
High$110.00
12-month Wall Street target range
Recent analyst rating changes · 30
Initiated
2026-10-07 · Barclays started covering EW at Overweight
Reiterated
2026-09-11 · BTIG reiterated Buy on EW
Upgrade
2026-07-25 · Leerink Partners upgraded EW from Market Perform to Outperform
Reiterated
2026-07-24 · JP Morgan reiterated Overweight on EW
Reiterated
2026-07-24 · Piper Sandler reiterated Overweight on EW
Reiterated
2026-07-16 · Truist Securities reiterated Hold on EW
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$51.3B
P/E (last 12 months)53.0
P/E (next 12 months, estimated)26.3
52-week range$74.66 – $96.29
Revenue growth (latest quarter vs a year ago)+13.6%
Dividend yieldNo dividend
Analyst consensusBuy (27)
Average analyst price target$101.39 (+10%)

What they do

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system.

Healthcare · Medical Devices
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
36th percentile in sector
C-
12-1 return: +4.7%
Percentile within its GICS sector across the S&P 1500.
Growth
70th percentile in sector
B
Revenue growth (YoY): +13.6%
Percentile within its GICS sector across the S&P 1500.
Value
23rd percentile in sector
D
Forward E/P: 3.9% · EBITDA/EV: 4.3%
Percentile within its GICS sector across the S&P 1500.
Profitability
59th percentile in sector
B-
Profit margin: +15.4% · Return on equity: +9.2%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
ranked 203 of 499 · 12-month momentum 16.7%
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

EW earningsNext report in 7 days
Next report · quarter Sep 2026
Wed Nov 4, 2026After the close
EPS consensus$0.74 range $0.72–$0.77
Revenue consensus$1.7B 24 analysts
Last 4 quarters · EPS vs estimate
Jul 23, 2026$0.78est $0.74+5.2%Above estimates
Apr 23, 2026$0.78est $0.73+7.3%Above estimates
Feb 10, 2026$0.58est $0.62−6.3%Below estimates
Oct 30, 2025$0.67est $0.59+12.6%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-24 11:20:02 ET
24-1025-0225-0425-0725-1026-0226-0426-070.000.78
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$1.7B+13.6%
2026-03-31$1.6B–
2025-12-31$1.6B–
2025-09-30$1.6B–
2025-06-30$1.5B–

News & catalysts

More news
DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally?
Zacks · Oct 22
Edwards Lifesciences faces stock risk ahead of trial results says Stifel
Investing.com · Oct 22
Rating changes
Initiated
2026-10-07 · Barclays started covering EW at Overweight
Reiterated
2026-09-11 · BTIG reiterated Buy on EW
Upgrade
2026-07-25 · Leerink Partners upgraded EW from Market Perform to Outperform
Reiterated
2026-07-24 · JP Morgan reiterated Overweight on EW
Reiterated
2026-07-24 · Piper Sandler reiterated Overweight on EW
Reiterated
2026-07-16 · Truist Securities reiterated Hold on EW

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Lippis Daniel J.
CVP, TAVR · 2026-10-08
Sell
$53.0K
Lippis Daniel J.
CVP, TAVR · 2026-09-11
Sell
$54.2K
Dahl Andrew M.
SVP, Corporate Controller · 2026-08-31
Sell
$49.5K
Bruls Annette
CVP, EMEACLA · 2026-08-28
Sell
$237.9K
Markowitz Wayne
CVP, JAPAC · 2026-08-26
Sell
$113.4K
Chopra Daveen
CVP, TMTT, Surgical & IHFM · 2026-08-26
Sell
$2.8M
Chopra Daveen
CVP, TMTT, Surgical & IHFM · 2026-08-26
Sell
$105.9K
Lippis Daniel J.
CVP, TAVR · 2026-08-11
Sell
$57.0K
Markowitz Wayne
CVP, JAPAC · 2026-07-30
Sell
$12.6K
Markowitz Wayne
CVP, JAPAC · 2026-07-28
Sell
$819.0K
Zovighian Bernard J
Director, CEO · 2026-07-27
Sell
$245.1K
None
None · None
Sell
–

Stats refreshed 2026-10-24 11:20:02 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026